[CRASH-2: the Clinical Randomization of an Antifibrinolytic in Significant Haemorrhage trial].
Arango
M
M
D000328:Adult; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D002648:Child; D006470:Hemorrhage / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D019106:Postoperative Hemorrhage / Q000453:epidemiology / Q000517:prevention & control; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D014148:Tranexamic Acid / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000150:complications
D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid